Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01366820 · ClinicalTrials.gov registry record · Phase 2
Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC
A Phase 2 study of Brain Injuries, sponsored by Neuren Pharmaceuticals Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 261
- Enrollment target
- 6
- Study locations
NCT01366820: Completed Phase 2 study of Brain Injuries, sponsored by Neuren Pharmaceuticals Limited.
NCT01366820 is a Phase 2 study of Brain Injuries that has completed, run by Neuren Pharmaceuticals Limited. The registered enrollment target is 261 participants, below the 319-participant average among 22 other Brain Injuries trials with a reported enrollment target (18% lower). The trial reports 6 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01366820, a Phase 2 study of Brain Injuries, has completed, sponsored by Neuren Pharmaceuticals Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 261 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG NNZ-2566
Study Locations (6)
California
- Arrowhead Regional Medical Center - Colton
- University of California, Davis Medical Center - Sacramento
Michigan
- Detroit Receiving Hospital and University Health Center - Detroit
- Sinai Grace Hospital - Detroit
Hawaii
- The Queen's Medical Center - Honolulu
Pennsylvania
- University of Pittsburgh Medical Center - Pittsburgh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 261 participants |
| Start Date | 2013-02 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
What the finished NCT01366820 record still lists
NCT01366820 is an interventional study that assigns participants to a tested intervention. The registered 261 participants enrollment target is mid-sized for trials with a published cap, below the 319-participant average among 22 other Brain Injuries trials with a reported enrollment target (18% lower).
The record links to 1 condition, with Brain Injuries appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01366820 lists 6 locations in 4 states (California, Michigan, Hawaii).
Frequently Asked Questions
What is clinical trial NCT01366820 about?
NCT01366820 is a clinical study titled "Study of NNZ-2566 in Patients With Traumatic Brain Injury Under EFIC". The purpose of this study is to determine whether NNZ-2566 is safe and effective in the treatment of Traumatic Brain Injury (TBI).
What is the current status of trial NCT01366820?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 261 participants. The study started on 2013-02. Estimated completion is 2016-01.
What conditions does trial NCT01366820 study?
This clinical trial studies the following conditions: Brain Injuries.
What interventions are being tested in trial NCT01366820?
The interventions under investigation include: Placebo (DRUG), NNZ-2566 (DRUG).
Who is sponsoring clinical trial NCT01366820?
This trial is sponsored by Neuren Pharmaceuticals Limited, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01366820 being conducted?
This trial has 6 study locations across California, Hawaii, Michigan, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Injuries
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01366820's enrollment target sits among peer trials
261 7th of 22 higher than 16 of 22 other Brain Injuries trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Injuries trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Remotely Supervised tDCS+ for Complex Attention in mTBI (Cognetric)
RECRUITING · NA
-
The Gut-Brain Axis During Neurorehabilitation; Prebiotic Treatment to Alter the Gut Microbiome and Neurologic Symptoms
RECRUITING · NA
-
Biomarker Role in Assessing Imaging Needs for Mild Cranial Trauma
RECRUITING · NA
-
Screening Emotions in Adolescents at the Hospital for mTBI
RECRUITING
-
Mobile Health Self-Management and Support System for Chronic and Complex Health Conditions
RECRUITING · NA
-
The HOME Study (Healthy Options Made Easy): Telehealth Nutrition Sessions for People Living With Brain Injury
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05124912 · 261 participants · NA
REMASTer: REcurrent Brain Metastases After SRS Trial
- NCT06559891 · 261 participants · NA
THRIVE- THerapeutic IntravasculaR Ultrasound (TIVUS™) REnal Denervation System Versus Sham for the Adjunctive Treatment of Hypertension
- NCT03713268 · 262 participants
Intraoperative OCT Guidance of Intraocular Surgery II
- NCT06074380 · 262 participants · Phase 4
Non Inferiority Trial Investigating Surfactants Administered Via MIST
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia